美国食品和药物管理局警告使用MS药物格拉蒂拉默酸盐有过敏反应风险, 自1996年以来报告了82例严重病例. FDA warns of anaphylaxis risk with MS drug glatiramer acetate, reporting 82 severe cases since 1996.

美国食品和药物管理局增加了有关与MS药物格拉蒂拉默酸盐 (Copaxone,Glatopa) 相关的过敏反应 (过敏反应) 的风险的警告. The FDA has added a warning about the risk of anaphylaxis, a severe allergic reaction, associated with the MS drug glatiramer acetate (Copaxone, Glatopa). 自1996年以来,报告了82例窒息病例,其中一些需要住院治疗或导致死亡。 Since 1996, 82 cases of anaphylaxis have been reported, some requiring hospitalization or leading to death. 美国食品和药物管理局建议在出现症状时立即就医,并敦促医疗保健提供者向患者提供这些风险的教育. The FDA advises immediate medical attention if symptoms occur, and healthcare providers are urged to educate patients on these risks.